AgingResearch.NewsJoin free

Bisabolangelone

Bisabolangelone has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 26, 2025: “Bisabolangelone targets CSF1R to impede osteoclastogenesis and attenuate estrogen-deficiency bone loss”.

Intervention

1 paper studies it3 findingsUpdated

PubChem

See all 1 papers on bisabolangelone

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Cells and mice: a single group. Worms or flies and humans: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Basic and Applied Basic Research Foundation of Guangdong Province and 4 more
  • Animals1

What did studies of bisabolangelone find?

3

Studies of bisabolangelone measured 3 outcomes: NLRP3 inflammasome, CSF1R and bone loss.

NLRP3 inflammasome

downin mouse cells1

1 study

  1. Bisabolangelone inhibits NLRP3 inflammasome in mouse cells (RANKL-stimulated RAW264.7 cells and BMMs).

    “Mechanistically, the compound quenched MAPK and Ca2+-NFATc1 cascades, blunted NF-κB transcriptional activity, curtailed reactive oxygen species generation, and restrained NLRP3 inflammasome assembly”

    CellsRANKL-stimulated RAW264.7 cells and BMMs

    Bisabolangelone targets CSF1R to impede osteoclastogenesis and attenuate estrogen-deficiency bone loss

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on NLRP3 inflammasome

CSF1R

downin mouse cells1

1 study

  1. Bisabolangelone inhibits CSF1R in mouse cells (binding shown by docking, molecular dynamics and CETSA; reversed by CSF1R overexpression).

    “Furthermore, Bisabolangelone inhibited osteoclast formation by binding to CSF1R, and overexpression of CSF1R reversed the inhibitory effects of Bisabolangelone on osteoclastogenesis.”

    Cellsbinding shown by docking, molecular dynamics and CETSA; reversed by CSF1R overexpression

    Bisabolangelone targets CSF1R to impede osteoclastogenesis and attenuate estrogen-deficiency bone loss

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on CSF1R

Bone loss

downin mice1

1 study

  1. Bisabolangelone protects against bone loss in mice (ovariectomy-induced estrogen deficiency).

    “Bisabolangelone treatment significantly protected against bone loss in ovariectomized mice by targeting CSF1R”

    Animalsovariectomy-induced estrogen deficiencybonefemales

    Bisabolangelone targets CSF1R to impede osteoclastogenesis and attenuate estrogen-deficiency bone loss

    Phytomedicine : international journal of phytotherapy and phytopharmacology

Latest

Related